Advanced in Inflammatory Breast Cancer

Dr. Minetta C. Liu

Oncology | Hematology Oncology
200 1st St Sw, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Inflammatory Breast Cancer
200 1st St Sw, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Minetta Liu is an Oncologist and a Hematologist Oncology provider in Rochester, Minnesota. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, and Lung Cancer.

Her clinical research consists of co-authoring 190 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in DC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

200 1st St Sw, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
Enrollment Status: Recruiting
Publish Date: August 08, 2025
Intervention Type: Procedure, Biological
Study Drug: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein
Study Phase: Phase 1
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study
Enrollment Status: Recruiting
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab
Study Phase: Phase 2
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
AURORA US: Prospective Biospecimen Repository in Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Procedure, Other
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Trastuzumab
Study Phase: Phase 1/Phase 2
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Enrollment Status: Suspended
Publish Date: August 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: ELU001
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

190 Total Publications

Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.
Personalized Circulating Tumor DNA Assay to Assess Long-Term Clinical Benefit in Patients with Advanced Melanoma.
Journal: Cancers
Published: October 16, 2025
Similar Doctors
Distinguished in Inflammatory Breast Cancer
Dr. Mina S. Hanna
Oncology | Hematology Oncology | Hematology
Distinguished in Inflammatory Breast Cancer
Dr. Mina S. Hanna
Oncology | Hematology Oncology | Hematology

Mayo Clinic Health System-Southeast Minnesota Region

404 W Fountain St, 
Albert Lea, MN 
 (51.9 miles away)
507-373-2384
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Mina Hanna is an Oncologist and a Hematologist Oncology provider in Albert Lea, Minnesota. Dr. Hanna is rated as a Distinguished provider by MediFind in the treatment of Inflammatory Breast Cancer. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Paget Disease of the Breast, and Colonoscopy. Dr. Hanna is currently accepting new patients.

Advanced in Inflammatory Breast Cancer
Dr. Jasmine Kamboj
Oncology | Hematology | Hematology Oncology
Advanced in Inflammatory Breast Cancer
Dr. Jasmine Kamboj
Oncology | Hematology | Hematology Oncology

Mayo Clinic Health System-Southeast Minnesota Region

701 Hewitt Blvd, 
Red Wing, MN 
 (37.5 miles away)
651-267-5000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Jasmine Kamboj is an Oncologist and a Hematologist in Red Wing, Minnesota. Dr. Kamboj is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Paget Disease of the Breast, Follicular Lymphoma, Lung Cancer, and Chronic Myelogenous Leukemia (CML). Dr. Kamboj is currently accepting new patients.

Distinguished in Inflammatory Breast Cancer
Dr. Prema Peethambaram
Hematology | Oncology
Distinguished in Inflammatory Breast Cancer
Dr. Prema Peethambaram
Hematology | Oncology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
 (0.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Prema Peethambaram is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Peethambaram is rated as an Advanced provider by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Breast Cancer, and Chronic Familial Neutropenia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liu's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile